Adaptive and maladaptive roles of different angiotensin receptors in the development of cardiac hypertrophy and heart failure

被引:4
|
作者
Bhullar, Sukhwinder K.
Dhalla, Naranjan S. [1 ]
机构
[1] Univ Manitoba, St Boniface Hosp, Inst Cardiovasc Sci, Albrechtsen Res Ctr, Winnipeg, MB, Canada
关键词
angiotensin II; angiotensin II receptors; adaptive cardiac hypertrophy; maladaptive cardiac hypertrophy; heart failure; II TYPE-2 RECEPTOR; LEFT-VENTRICULAR HYPERTROPHY; ROSTRAL VENTROLATERAL MEDULLA; CONVERTING ENZYME-INHIBITORS; SYMPATHETIC AFFERENT REFLEX; VASCULAR SMOOTH-MUSCLE; OXIDATIVE STRESS; BLOOD-PRESSURE; AT(1) RECEPTOR; AT(2) RECEPTORS;
D O I
10.1139/cjpp-2023-0226
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Angiotensin II (Ang II) is formed by the action of angiotensin-converting enzyme (ACE) in the renin-angiotensin system. This hormone is known to induce cardiac hypertrophy and heart failure and its actions are mediated by the interaction of both pro-and antihypertrophic Ang II receptors (AT1R and AT2R). Ang II is also metabolized by ACE 2 to Ang-(1-7), which elicits the activation of Mas receptors (MasR) for inducing antihypertrophic actions. Since heart failure under different pathophysiological situations is preceded by adaptive and maladaptive cardiac hypertrophy, we have reviewed the existing literature to gain some information regarding the roles of AT1R, AT2R, and MasR in both acute and chronic conditions of cardiac hypertrophy. It appears that the activation of AT1R may be involved in the development of adaptive and maladaptive cardiac hypertrophy as well as subsequent heart failure because both ACE inhibitors and AT1R antagonists exert beneficial effects. On the other hand, the activation of both AT2R and MasR may prevent the occurrence of maladaptive cardiac hypertrophy and delay the progression of heart failure, and thus therapy with different activators of these antihypertrophic receptors under chronic pathological stages may prove beneficial. Accordingly, it is suggested that a great deal of effort should be made to develop appropriate activators of both AT2R and MasR for the treatment of heart failure subjects.
引用
收藏
页码:86 / 104
页数:19
相关论文
共 50 条
  • [41] The Role of PPARs in Pathological Cardiac Hypertrophy and Heart Failure
    Liao, Hai-Han
    Jia, Xu-Hui
    Liu, Huang-Jun
    Yang, Zheng
    Tang, Qi-Zhu
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (11) : 1677 - 1686
  • [42] Vitamin D Therapy in Cardiac Hypertrophy and Heart Failure
    Wu-Wong, J. Ruth
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (18) : 1794 - 1807
  • [43] Cardiac Hypertrophy and Heart Failure Development Through Gq and CaM Kinase II Signaling
    Mishra, Shikha
    Ling, Haiyun
    Grimm, Michael
    Zhang, Tong
    Bers, Don M.
    Brown, Joan Heller
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2010, 56 (06) : 598 - 603
  • [44] Cytokines and cardiac hypertrophy: Roles of angiotensin II and basic fibroblast growth factor
    Kaye, DM
    Kelly, RA
    Smith, TW
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1996, 23 : S136 - S141
  • [45] Impact of polyphenols on heart failure and cardiac hypertrophy: clinical effects and molecular mechanisms
    Hedayati, Neda
    Yaghoobi, Alireza
    Salami, Marziyeh
    Gholinezhad, Yasaman
    Aghadavood, Farnaz
    Eshraghi, Reza
    Aarabi, Mohammad-Hossein
    Homayoonfal, Mina
    Asemi, Zatollah
    Mirzaei, Hamed
    Hajijafari, Mohammad
    Mafi, Alireza
    Rezaee, Malihe
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [46] Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets
    Tham, Yow Keat
    Bernardo, Bianca C.
    Ooi, Jenny Y. Y.
    Weeks, Kate L.
    McMullen, Julie R.
    ARCHIVES OF TOXICOLOGY, 2015, 89 (09) : 1401 - 1438
  • [47] Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts
    Yamamoto, K
    Masuyama, T
    Sakata, Y
    Mano, T
    Nishikawa, N
    Kondo, H
    Akehi, N
    Kuzuya, T
    Miwa, T
    Hori, M
    CARDIOVASCULAR RESEARCH, 2000, 47 (02) : 274 - 283
  • [48] Catecholamines, cardiac β-adrenergic receptors, and heart failure
    Lefkowitz, RJ
    Rockman, HA
    Koch, WJ
    CIRCULATION, 2000, 101 (14) : 1634 - 1637
  • [49] Echocardiographic markers of cardiac amyloidosis in patients with heart failure and left ventricular hypertrophy
    Polo, Jorge Melero
    Barrenechea, Ana Roteta Unceta
    Marti, Pablo Revilla
    Gutierrez, Anyuli Gracia
    Juana, Esperanza Bueno
    Ayala, Saida Atienza
    Arregui, Miguel Angel Aibar
    CARDIOLOGY JOURNAL, 2023, 30 (02) : 266 - 275
  • [50] Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy
    Deinum, J
    van Gool, JMG
    Kofflard, MJM
    ten Cate, FJ
    Danser, AHJ
    HYPERTENSION, 2001, 38 (06) : 1278 - 1281